Literature DB >> 32601573

Chemotherapy in a Breast Cancer Patient Heterozygous Carrier of Ornithine Transcarbamylase Deficiency.

Magda Palka-Kotlowska1, Luis Cabezón-Gutiérrez2, Sara Custodio-Cabello2, PIlar Quijada-Fraile3, Silvia Chumillas-Calzada3.   

Abstract

Urea cycle disorders (UCDs) are an unusual genetic condition that may lead to hyperammonemia in catabolic situations such as surgery, infections or chemotherapy administration. Without specific treatment, it causes life-threatening encephalopathy. We present the case of a young woman, heterozygous carrier of ornithine transcarbamylase deficiency (OTCD) with breast cancer, who was treated with surgery, chemotherapy, radiotherapy and hormone therapy while following a protocol to minimize the risk of metabolic decompensation due to her condition.
Copyright © 2020, Palka-Kotlowska et al.

Entities:  

Keywords:  breast cancer; chemotherapy; ornithine transcarbamylase deficiency; urea cycle deficiency

Year:  2020        PMID: 32601573      PMCID: PMC7317123          DOI: 10.7759/cureus.8301

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

1.  Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder.

Authors:  Megan Peters; Janine Zee-Cheng; Ashley Kuhl; Jennifer Orozco; Everett Lally; Jessica Scott Schwoerer
Journal:  Pediatr Blood Cancer       Date:  2018-05-18       Impact factor: 3.167

Review 2.  Exome sequencing as a tool for Mendelian disease gene discovery.

Authors:  Michael J Bamshad; Sarah B Ng; Abigail W Bigham; Holly K Tabor; Mary J Emond; Deborah A Nickerson; Jay Shendure
Journal:  Nat Rev Genet       Date:  2011-09-27       Impact factor: 53.242

Review 3.  A longitudinal study of urea cycle disorders.

Authors:  Mark L Batshaw; Mendel Tuchman; Marshall Summar; Jennifer Seminara
Journal:  Mol Genet Metab       Date:  2014-08-10       Impact factor: 4.797

4.  Acute hyperammonemic encephalopathy in a non-cirrhotic patient with hepatocellular carcinoma reversed by arginine therapy.

Authors:  Shivani S Shinde; Prashant Sharma; Mellar P Davis
Journal:  J Pain Symptom Manage       Date:  2014-04       Impact factor: 3.612

5.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

6.  Current strategies for the management of neonatal urea cycle disorders.

Authors:  M Summar
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

Review 7.  Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision.

Authors:  Johannes Häberle; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Daniela Karall; Martin Lindner; Hanna Mandel; Diego Martinelli; Guillem Pintos-Morell; René Santer; Anastasia Skouma; Aude Servais; Galit Tal; Vicente Rubio; Martina Huemer; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2019-05-15       Impact factor: 4.982

8.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

9.  Unusual causes of hyperammonemia in the ED.

Authors:  Te-I Weng; Frank Fuh-Yuan Shih; Wen-Jone Chen
Journal:  Am J Emerg Med       Date:  2004-03       Impact factor: 2.469

10.  Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report.

Authors:  Takatsugu Ogata; Hironaga Satake; Misato Ogata; Yukimasa Hatachi; Hisateru Yasui
Journal:  Case Rep Oncol       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.